作者
Arnau Busquets-Garcia, Maria Gomis-González, Thomas Guegan, Carmen Agustín-Pavón, Antoni Pastor, Susana Mato, Alberto Pérez-Samartín, Carlos Matute, Rafael De La Torre, Mara Dierssen, Rafael Maldonado, Andrés Ozaita
发表日期
2013/5
期刊
Nature medicine
卷号
19
期号
5
页码范围
603-607
出版商
Nature Publishing Group US
简介
Fragile X syndrome (FXS), the most common monogenic cause of inherited intellectual disability and autism, is caused by the silencing of the FMR1 gene, leading to the loss of fragile X mental retardation protein (FMRP), a synaptically expressed RNA-binding protein regulating translation. The Fmr1 knockout model recapitulates the main traits of the disease. Uncontrolled activity of metabotropic glutamate receptor 5 (mGluR5), and mammalian target of rapamycin (mTOR) signaling,, seem crucial in the pathology of this disease. The endocannabinoid system (ECS) is a key modulator of synaptic plasticity, cognitive performance, anxiety, nociception and seizure susceptibility, all of which are affected in FXS. The cannabinoid receptors CB1 (CB1R) and CB2 (CB2R) are activated by phospholipid-derived endocannabinoids, and CB1R-driven long-term regulation of synaptic strength, as a consequence of mGluR5 …
引用总数
20132014201520162017201820192020202120222023202410272528362225241620178
学术搜索中的文章